Topics · healthcare

Markdown

HSA Post-marketing Vigilance Guidance 2026

HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.

Record details

Description
HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.
Also known as
HSA post-marketing vigilance, therapeutic product adverse-event reporting Singapore, CTGTP vigilance guidance
Evidence profile
mixed
Part of
Healthcare

Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force.

Collection as of 2026-11-22 · An expanding collection. Published counts show available knowledge, not complete coverage of Singapore. Machine-readable: JSON · sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026